Nexalin says open-label pilot trial data show 77.8% anxiety response with DIFS brain-stimulation device

Nexalin Technology, Inc.

Nexalin Technology, Inc.

NXL

0.00
  • Nexalin flagged two clinical abstracts accepted for the 2026 NYC Neuromodulation Conference; results will be presented at the meeting.
  • Data came from an open-label pilot trial in adults with generalized anxiety disorder and comorbid insomnia using its non-invasive brain-stimulation device.
  • Outcomes showed broad symptom improvement across anxiety, depressive symptoms, insomnia, and quality of life, with benefits described as durable post-treatment.
  • Safety profile appeared favorable, with no serious adverse events reported in the study.
  • Disclosure supports its push toward international commercialization, including a potential Brazil launch, alongside an FDA De Novo pathway strategy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexalin Technology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606160915PRIMZONEFULLFEED9747123) on June 16, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.